Bevacizumab biosimilar (Boan Biopharma)

贝伐珠单抗生物类似物（博安生物）

Report date: 2025/12/10 14:38:26

Base Information

Drug NameBevacizumab biosimilar (Boan Biopharma)
Drug Alias Name贝伐珠单抗生物类似物（博安生物）bevacizumab biosimilar（Shandong Luye Pharmaceutical）贝伐人源化单抗生物类似物（博安生物）bevacizumab biosimilar (Boan Biopharma)贝伐单抗生物类似物（博安生物） +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/04/30
Country/TerritoryBrazilMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Boan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcShandong Boan Biotechnology Co Ltd
Inactive CompaniesLuye Pharma Group Ltd
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG